A308080 Share Price Performance
₩0
-3110.00 (-100.00%)
Price ₩0
Share Pricen/a
ViGenCell Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A308080 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
ViGenCell Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- -612.64
- 1.54%
- -4,502.18%
- 13.0%
About A308080
- Founded
- 2013
- Employees
- 64
- CEO
- WebsiteView website
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
